GlassScriptPhysician profile
Dipal K Divecha
NPI 1023351384
$15,536.97
in general payments reported to CMS, 2019-2025
40 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $828 · 2022: $827 · 2023: $860 · 2024: $1,183 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,403 · Food and Beverage: $6,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,402.61 |
| Food and Beverage | $6,478.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $7,837.30 | 2021-2025 | Omnipod, Omnipod |
| Amgen INC. | $1,129.54 | 2021-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $951.09 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $563.67 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Corcept Therapeutics | $401.72 | 2023-2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $397.02 | 2025 | Yorvipath |
| Radius Health, INC. | $364.54 | 2022-2025 | Tymlos |
| Abbvie INC. | $309.08 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $298.80 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $277.30 | 2023-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $269.86 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Xeris Pharmaceuticals, INC. | $230.70 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.35 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $216.36 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $206.37 | 2021-2024 | Farxiga |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $205.08 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Ibsa Pharma INC. | $182.53 | 2021-2025 | Licart, Tirosint, Tirosint |
| Sanofi-Aventis U.S. LLC | $174.78 | 2021-2025 | |
| Mannkind Corporation | $154.52 | 2021-2025 | |
| Cequr Corporation | $145.25 | 2024-2025 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $130.77 | 2022-2025 | Strensiq |
| Antares Pharma, INC. | $118.30 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Madrigal Pharmaceuticals | $83.57 | 2025 | Rezdiffra |
| Amneal Pharmaceuticals LLC | $81.00 | 2025 | Unithroid |
| Medtronic, INC. | $73.70 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Alvogen INC | $68.39 | 2022-2025 | Teriparatide |
| Avvisto Therapeutics, LLC | $67.70 | 2025 | Cycloset |
| Zealand Pharma US, INC. | $64.21 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $55.06 | 2024-2025 | |
| Tolmar, INC. | $51.36 | 2025 | Jatenzo |
| Neurocrine Biosciences, INC. | $30.01 | 2025 | |
| Pfizer INC. | $27.16 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $21.73 | 2024 | |
| Verity Pharmaceuticals INC. | $20.68 | 2025 | Tlando |
| Sequel Med Tech, LLC | $19.49 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $19.16 | 2023 | Signifor Lar, Isturisa |
| Azurity Pharmaceuticals, INC. | $17.30 | 2025 | Azmiro |
| Currax Pharmaceuticals LLC | $16.76 | 2025 | Contrave |
| Acella Pharmaceuticals, LLC | $15.22 | 2025 | NP Thyroid 60 |
| Amarin Pharma, INC. | $14.54 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipal Divecha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.